Yasumasa Ohta
mRNA Technology Leader Meiji Seika Pharma
My scientific background is primarily in biological research within Japanese pharmaceutical companies, focusing on areas such as microbial fermentation, molecular biology, and biotechnology engineering. Drawing on this experience, I successfully led biosimilar monoclonal antibody (mAb) research and development at my current company, Meiji.
In my current role as mRNA Technology Leader, I am responsible for the development and regulatory management of sa-mRNA vaccines in Japan.
Seminars
With organizations such as the Korean Disease Control and Prevention Agency (KDCA), the Korean Ministry of Health, and The RIGHT Foundation, driving investment into next-generation mRNA technologies, collaboration between Korean and international stakeholders to achieve success has never been more critical. They will also be key to advancing regional manufacturing capabilities and ensuring equitable access to vaccines worldwide, particularly across low- and middle-income countries (LMICs).
Hear from vaccine experts as they shed light on strategies to overcome the next pandemic through RNA technology innovations including:
- How to develop key biopharma partnerships to achieve the impact on global vaccine equity?
- How to leverage best practices for mRNA vaccine R&D and local manufacturing in LMICs?
- Outlining current bottlenecks with scaling up to ensure regional capacity and global availability of mRNA vaccines
With the rise of complexity in mRNA modalities as an application or tool, now better innovations and approaches are now required to ensure scalable manufacturing and CMC process towards the clinic. This workshop will dive into new CMC and regulatory pathways to go from drug substance to final product with new processes, strategies, and manufacturing insights across the Asia-Pacific Region.
Join this discussion to gain key insights on:
- From Lab to GMP: Practical strategies for accelerating mRNA process development, quality control and regulatory alignment – Insights from Australia’s end-to-end RNA ecosystem
- CMC and regulatory strategies for self-amplifying mRNA vaccine manufacturing in Japan
- Technical process development and CMC scale-up strategies – Real-world approaches to accelerating mRNA manufacturing while maintaining quality and analytics robustness for domestic production
